These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 9399405)

  • 1. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.
    Kakkar VV
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):9-19. PubMed ID: 9399405
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE).
    Kakkar VV
    Thromb Haemost; 1995 Jul; 74(1):364-8. PubMed ID: 8578486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 7. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When can the patient with deep venous thrombosis begin to ambulate?
    Aldrich D; Hunt DP
    Phys Ther; 2004 Mar; 84(3):268-73. PubMed ID: 14984299
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical potential of low molecular weight heparins.
    Messmore HL
    Semin Thromb Hemost; 1989 Oct; 15(4):405-8. PubMed ID: 2554501
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?
    Agnelli G
    Haematologica; 1995; 80(2 Suppl):78-83. PubMed ID: 7628776
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and economic impact of low-molecular weight heparins in managed care. Introduction.
    Am J Manag Care; 2000 Nov; 6(20 Suppl):S1024-5. PubMed ID: 11484301
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
    Bergqvist D; Siegbahn A
    Lakartidningen; 2002 Jul; 99(28-29):3039-41. PubMed ID: 12170516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European consensus statement on the prevention of venous thromboembolism. European Consensus Conference, Windsor, U.K., November, 1991.
    Haas S
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S5-8; discussion S9-10. PubMed ID: 8180330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rationale for long-term prophylaxis of venous thromboembolism.
    Agnelli G; Mancini GB; Biagini D
    Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty.
    Wade WE
    Clin Ther; 1998; 20(2):347-51. PubMed ID: 9589825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting an agent for prophylaxis of venous thromboembolism.
    Myers J
    Am J Health Syst Pharm; 2006 Dec; 63(24):2448-50. PubMed ID: 17158692
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylaxis of venous thromboembolism: the old and the new.
    Pini M
    Haematologica; 1995; 80(2 Suppl):66-77. PubMed ID: 7628774
    [No Abstract]   [Full Text] [Related]  

  • 18. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience of a low molecular weight heparin (Fragmin) in the prevention of thromboembolism after total hip replacement.
    Eriksson BI; Kälebo P; Risberg B
    Semin Thromb Hemost; 1993; 19 Suppl 1():122-7. PubMed ID: 8395714
    [No Abstract]   [Full Text] [Related]  

  • 20. [The prevention of thromboembolic disease in medical patients: heparin-calcium or low-molecular-weight heparin?].
    de los Santos-Sastre S
    An Med Interna; 1993 Sep; 10(9):465-6. PubMed ID: 8218806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.